Skip to content
Open access

Modern methods of treatment of anaplastic thyroid cancer (clinical case)

Sep 2026 · Head and neck tumors (HNT) · Vol 16, pp. 99-108 · 0 citations · 5 references

TL;DR

The presented clinical case demonstrates the importance of molecular profiling and the use of a multidisciplinary approach, as well as the possibility of using active surgical management in the oligoprogression of anaplastic thyroid cancer.

Abstract

The article presents a clinical case of treating stage IV anaplastic thyroid cancer with a V600E mutation in the BRAF gene and distant metastasis (including metastases to the right ventricle of the heart and the right adrenal gland). At the first stage, targeted therapy (dabrafenib + trametinib) was performed, which allowed achieving pronounced clinico-metabolic regression and performing radical multi-stage surgical treatment. Subsequently, with the development of drug resistance and the detection of high expression of programmed cell death 1 ligand (PD-L1) (Combined Positive Score (CPS) – the ratio of the number of PD-L1-positive cells to the total number of tumor cells = 100), immunotargeted therapy with pembrolizumab in combination with lenvatinib was prescribed, resulting in a partial metabolic response. Despite the subsequent disease progression, overall survival from the time of diagnosis was 46 months. The presented clinical case demonstrates the importance of molecular profiling and the use of a multidisciplinary approach, as well as the possibility of using active surgical management in the oligoprogression of anaplastic thyroid cancer.

Read PDF

Similar papers

Case report Open access Oct 2026

Ivonescimab combined with radiotherapy in the treatment of advanced lung adenocarcinoma with high expression of PD-L1: A case report

The optimal sequencing of immunotherapy and radiotherapy in non-small cell lung cancer (NSCLC) remains unclear. The present study reports a case of advanced lung adenocarcinoma (cT4N2bM1a, stage IVa) with a programmed death-ligand 1 (PD-L1) tumor proportion score of 90% and TP53 mutation. The patient received first-lin...

Qi Zhou, Bo Yang, Hong-Yi Cai et al. · 0 citations
Review Open access Nov 2026

Revisiting the Role of Chemotherapy in Advanced Medullary Thyroid Carcinoma: A Case Report and Review of the Literature.

BACKGROUND Chemotherapy has been always considered scarcely or completely ineffective in the treatment of metastatic and progressive MTC. CASE REPORT We report the case of a 45-year-old man who underwent total thyroidectomy and lymphadenectomy in May 2023 for bilateral MTC with extrathyroidal extension and 2/23 metas...

M. Trevisan, Giulia Puxeddu, Martina Violati et al. · 0 citations
Open access Oct 2026

Clinical case of treatment of a patient with metastatic colorectal cancer with a POLE-mutation

Introduction. Metastatic colorectal cancer remains one of the major challenges in modern oncology due to its high incidence, frequent diagnosis at advanced stages, and the limited efficacy of standard lines of systemic therapy. In recent years, molecular genetic profiling of tumors has become increasingly important,...

A. B. Sunyaykin, V. Apanasevich, S. S. Startsev et al. · 0 citations
Review Open access Oct 2026

TURNING THE TIDE: BRAF-TARGETED THERAPY ENABLING SURGICAL DOWNSTAGING IN STAGE IVC ANAPLASTIC THYROID CANCER

Anaplastic thyroid cancer (ATC) constitutes less than 2% of thyroid cancer but accounts for up to 50% of thyroid cancer mortality, with a median survival of 3–6 months. All ATC is Stage IV at diagnosis by definition. BRAF V600E-mutant disease is the only molecularly defined subset with FDA-approved targeted therapy...

F. A. Francis, N. Kannur, Vijay Pillai et al. · 0 citations
Open access Oct 2026

The impact of BRAF mutation on survival of patients with metastatic colorectal cancer depending on the type of surgical and systemic treatment

Introduction . Metastatic colorectal cancer (mCRC) remains a leading cause of cancer-related mortality worldwide. BRAF mutations (predominantly V600E) occur in 5–10% of mCRC cases and are associated with an aggressive disease phenotype, poor response to conventional chemotherapy, and dismal prognosis. In the Russian...

A. S. Fattakhova, S. V. Cheporov, N. P. Shiryaev · 0 citations
Open access 2026

Personalized Approach to Therapy Selection in a Patient with ALK-Positive Non-Small Cell Lung Cancer: A Clinical Case

Anaplastic lymphoma kinase-positive non-small cell lung cancer (ALK-positive NSCLC) is a molecularly defined subtype of lung cancer in which the optimal sequencing of systemic therapy is essential for achieving long-term disease control. Progression involving the central nervous system (CNS) represents a particular cli...

A. Bekisheva, G. Akylzhanova, F. Olzhayev · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.